CL2022000156A1 - Degradador selectivo del receptor de estrógeno - Google Patents
Degradador selectivo del receptor de estrógenoInfo
- Publication number
- CL2022000156A1 CL2022000156A1 CL2022000156A CL2022000156A CL2022000156A1 CL 2022000156 A1 CL2022000156 A1 CL 2022000156A1 CL 2022000156 A CL2022000156 A CL 2022000156A CL 2022000156 A CL2022000156 A CL 2022000156A CL 2022000156 A1 CL2022000156 A1 CL 2022000156A1
- Authority
- CL
- Chile
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degrader
- chromen
- azetidin
- Prior art date
Links
- 229940125944 selective estrogen receptor degrader Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- DVZLOPUYTKPWHJ-MPWQXXDYSA-N (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol Chemical compound FC=1C=C(C=C(C=1)F)C=1[C@@H](OC2=CC(=CC=C2C=1C)O)C1=CC=C(C=C1)\C=C\CN1CC(C1)CF DVZLOPUYTKPWHJ-MPWQXXDYSA-N 0.000 abstract 1
- DVZLOPUYTKPWHJ-NSCUHMNNSA-N 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol Chemical compound FC=1C=C(C=C(C=1)F)C=1C(OC2=CC(=CC=C2C=1C)O)C1=CC=C(C=C1)\C=C\CN1CC(C1)CF DVZLOPUYTKPWHJ-NSCUHMNNSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029554 | 2019-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000156A1 true CL2022000156A1 (es) | 2022-11-18 |
Family
ID=71842730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000156A CL2022000156A1 (es) | 2019-07-22 | 2022-01-22 | Degradador selectivo del receptor de estrógeno |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) * | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| US12391667B2 (en) | 2019-07-22 | 2025-08-19 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| DE69023906T2 (de) | 1990-08-09 | 1996-04-11 | Council Scient Ind Res | Benzopyrane und Verfahren zu deren Herstellung. |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| BR112014014767A2 (pt) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | novos compostos de benzopirano, composições e usos dos mesmos |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| BR112015030595A2 (pt) * | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| CN103879283B (zh) * | 2014-03-10 | 2019-01-15 | 浙江吉利汽车研究院有限公司 | 一种电动车辆 |
| CN107406433A (zh) * | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US10865199B2 (en) * | 2015-10-27 | 2020-12-15 | Sun Pharma Advanced Research Company Limited | Heterocyclic antiestrogens |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
-
2020
- 2020-07-22 US US16/936,022 patent/US11014915B2/en active Active
- 2020-07-22 JP JP2022504655A patent/JP2022541938A/ja active Pending
- 2020-07-22 BR BR112022001285A patent/BR112022001285A2/pt not_active IP Right Cessation
- 2020-07-22 AU AU2020317099A patent/AU2020317099A1/en not_active Abandoned
- 2020-07-22 CA CA3148592A patent/CA3148592A1/en active Pending
- 2020-07-22 CN CN202080053315.6A patent/CN114302879A/zh active Pending
- 2020-07-22 WO PCT/IB2020/056914 patent/WO2021014386A1/en not_active Ceased
- 2020-07-22 MX MX2022001013A patent/MX2022001013A/es unknown
- 2020-07-22 EP EP20747136.8A patent/EP4003525A1/en not_active Withdrawn
- 2020-07-22 KR KR1020227005904A patent/KR20220046586A/ko not_active Ceased
- 2020-07-22 PE PE2022000135A patent/PE20221588A1/es unknown
- 2020-07-22 PH PH1/2022/550182A patent/PH12022550182A1/en unknown
-
2021
- 2021-05-05 US US17/308,501 patent/US20210261534A1/en not_active Abandoned
-
2022
- 2022-01-22 CL CL2022000156A patent/CL2022000156A1/es unknown
- 2022-01-23 IL IL290036A patent/IL290036A/en unknown
- 2022-01-25 ZA ZA2022/01157A patent/ZA202201157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201157B (en) | 2023-07-26 |
| JP2022541938A (ja) | 2022-09-28 |
| CA3148592A1 (en) | 2021-01-28 |
| BR112022001285A2 (pt) | 2022-03-22 |
| WO2021014386A1 (en) | 2021-01-28 |
| PE20221588A1 (es) | 2022-10-10 |
| MX2022001013A (es) | 2022-02-22 |
| US20210261534A1 (en) | 2021-08-26 |
| KR20220046586A (ko) | 2022-04-14 |
| US20210024504A1 (en) | 2021-01-28 |
| IL290036A (en) | 2022-03-01 |
| CN114302879A (zh) | 2022-04-08 |
| AU2020317099A1 (en) | 2022-02-24 |
| PH12022550182A1 (en) | 2022-11-14 |
| US11014915B2 (en) | 2021-05-25 |
| EP4003525A1 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221588A1 (es) | Degradador selectivo del receptor de estrogeno | |
| MX2021009569A (es) | Procesos y compuestos. | |
| UY38767A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| PH12021550296A1 (en) | Substituted indoles and methods of use thereof | |
| MX2023010043A (es) | Moduladores del receptor de androgenos y metodos para su uso. | |
| MX392461B (es) | Moduladores de receptores estrogénicos | |
| UY32352A (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
| UY32996A (es) | Antagonistas del receptor crth2 basados en indol | |
| EA201792394A2 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
| EP4212532A3 (en) | Mitragynine analogs and uses thereof | |
| UY30292A1 (es) | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico | |
| ZA202301275B (en) | Indole compounds as androgen receptor modulators | |
| PH12021550381A1 (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | |
| UY33118A (es) | Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos | |
| MX378389B (es) | Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
| PH12021550839A1 (en) | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease | |
| MX2021009694A (es) | Compuestos biciclicos sustituidos como moduladores del receptor farnesoide x. | |
| MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
| WO2019123482A8 (en) | Pharmaceutical composition for the treatment of cancer | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| UY33722A (es) | Oxazolidinonas como moduladores de mglur5 | |
| ECSP088878A (es) | Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1) | |
| CR20240353A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| MX2021007687A (es) | Sales novedosas de degradadores selectivos de receptores de estrogeno. | |
| PE20221454A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 |